Pharmaceutical Companies

Manufacturing sentiment positive in Q4 despite higher costs: Ficci survey

Growth sentiment in India's manufacturing sector stays positive during the fourth quarter of FY26 despite rising input costs and geopolitical uncertainties, according to a survey released on Wednesday. The only impact seen was in the capacity utilization, which saw a little dip at nearly 72 per cent compared to the previous quarter. However, the future investment outlook is steady for the next six months, showed the latest FICCI survey for the January-March period of FY26. The survey assessed the performance and sentiments for January-March 2025-26 of manufacturers for eight major sectors, including automobile, capital goods, chemical, fertilizer & pharmaceuticals, electronics & electricals, machine tools, metal, and textiles. Responses have been drawn from over 250 manufacturing units from both large and SME segments with a combined annual turnover of over Rs 8 lakh crore. "The survey continued to reflect sustained growth and increasing optimism for India's manufacturing ...

Race to deploy LLM tools must be matched by AI safeguards: Nicolas Miailhe

AI Safety Connect co-founders say safety frameworks must evolve as fast as tools built on large language models, warning that gaps between capability and control create systemic risks

Indian CDMOs expand capacity as demand for complex drug work rises

Indian CDMOs are expanding manufacturing capacity and investing in advanced technologies as global pharma companies increasingly outsource complex drug development and manufacturing work

Morepen Labs wins ₹825 crore long-term CDMO deal with global drugmaker

Morepen Labs has secured a ₹825 crore multi-year CDMO mandate from a global pharma major, with supplies set to begin in 4-5 months and execution running through Q1 FY27

JM Financial flags growth concerns in Mankind Pharma; initiates with Reduce

JM Financial raised concerns around Mankind Pharma's recent BSV acquisition, which was executed at a high valuation and is expected to dilute return on capital

IPA members commit $50 million to set up pharma skilling academy PAGE

IPA member firms have committed $50 million to launch PAGE, an industry-led academy to boost pharmaceutical manufacturing skills, quality systems and regulatory compliance in India

Antique maintains 'Buy' on Concord Biotech; sees strong API, CDMO growth

Antique expects the Concord to report revenue, Ebitda and PAT CAGR of 18 per cent, 17 per cent and 19 per cent, respectively, with margins remaining stable at around 42 per cent over FY25-28E

Odisha unveils Pharma, MedTech Policy 2025, eyes ₹25,000 crore investment

The Odisha government on Tuesday unveiled Pharmaceutical and Medical Devices Policy-2025, aiming to attract investment of Rs 25,000 crore and create 1 lakh jobs by 2030. Chief Minister Mohan Charan Majhi launched the new policy here at the Odisha Pharma Summit-2025 in the presence of Industries Minister Sampad Chandra Swain and senior government officers. Speaking on the occasion, Industries Department's Additional Chief Secretary Hemant Sharma said India imports about 85 per cent of medical devices from other countries, and there is a huge opportunity for this sector. As a lot of units of pharmaceutical and medical devices are expected to come up in the next five years, Odisha must make an attempt to become a part of this endeavour, Sharma said. Under the policy, the state offers a 50 per cent subsidy on concessional land cost for units employing more than 200 Odisha-domiciled skilled staff. The government also offered a 30 per cent capital subsidy on eligible plant and machinery

Emkay predicts strong upside in Ipca Labs shares on India, export growth

Emkay Global initiated coverage of Ipca Labs shares with 'Buy' rating and a share price target of ₹1,700 -- a 19 per cent upside from current levels

Zydus Lifesciences, RK Pharma sign deal for licensing, commercialisation

Zydus Lifesciences Ltd on Wednesday said it has entered into an exclusive licensing and commercialisation agreement with RK Pharma Inc of the US for a new sterile injectable oncology supportive care product for the US market. Under the terms of this agreement, RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA (new drug application) submission and commercialisation of the product in the US, the company said in a regulatory filing. The product is expected to be filed in 2026 and will provide a formulation that is intended to provide reduced dosing error and enhanced compliance of healthcare professionals, it added. "This partnership reinforces our commitment to delivering high-quality, affordable medicines and improving patient care," Zydus Lifesciences Managing Director Sharvil Patel said. RK Pharma Founder and Executive Chairman Ravishanker Kovi said, "Our collaboration with Zydus, a company with robust regulatory expertise and

A deadly dose of neglect: Bitter truth behind cough syrup scare

Bottled negligence: DEG contamination exposes gaps in inspections, leaving pharma units from Gujarat to Kerala under the microscope

Eli Lilly to invest over $1 billion in India to boost manufacturing

Eli Lilly, which launched its obesity drug Mounjaro in India earlier this year, plans to invest $1 billion to strengthen manufacturing partnerships and set up a new Hyderabad facility

Pharma firms get one-month extension to submit declarations under UCPMP

The Department of Pharmaceuticals extends the deadline for pharma companies to file self-declarations, ensuring compliance with the Uniform Code for Pharmaceutical Marketing Practices (UCPMP)

Samsung's PLI journey ends. Will India's production incentive boom hold?

Samsung has completed its PLI cycle, claiming ₹1,000-1,200 crore in FY25. With payouts ending, India must evaluate whether the scheme builds lasting manufacturing ecosystems

Cipla Q1 preview: Net profit may jump up to 4%, revenue by 8% YoY

Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, 2025

Here's what brokerages expect from Dr Reddy's Labs ahead of Q1 show

Dr Reddy's Labs Q1 preview: The company's net profit is expected to come at ₹1,460 crore, marking around 4.9 per cent Y-o-Y increase, on average, as against ₹1,392.4 crore in Q1 FY25

China's biotech surge shifts global drug innovation, stirs US tension

Top regulators like the US FDA and EMA are fast-tracking more Chinese drugs, granting priority review and breakthrough designations as they gain confidence in China's biotech innovation

Anthem Biosciences expands manufacturing capacity ahead of ₹3,395-cr IPO

CRDMO firm Anthem Biosciences expands peptide and API production, with Unit 4 under development, as it prepares for a Rs 3,395-crore IPO opening on July 14

Biocon's ₹4,500 crore equity raise to reduce debt by FY26, says S&P

S&P says Biocon will bring down adjusted debt to Rs 20,000 crore by FY26 through equity issuance, with strong cash flows aiding deleveraging and future capex needs

Rekha Jhunjhunwala portfolio stock soars 17%; zooms over 950% in 2 years

Shares of Wockhardt hit an all-time high of ₹1,809.95, as they rallied 17% on the BSE in Wednesday's intra-day trade surpassed its previous high of ₹1,678.60 touched on February 6, 2025.